Featured Content

Winston Wong, PharmD
President, W-Squared Group

70-Gene Signature Not Cost-Effective in Breast Cancer

(Betty Hardwick Center/HealthDay News) Oct 17, 2014 — For patients with node-negative breast cancer (NNBC), the 70-gene signature is unlikely to be cost-effective for guiding adjuvant chemotherapy decision making, according to a study published online Oct. 6 in the Journal of Clinical Oncology.

Commentary: It would be interesting to see their analysis of OncoTypeDx in the same study setting. I know costs are very different...



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

AstraZeneca Ovarian-Cancer Drug Wins EU Agency’s Backing

(Bloomberg) Oct 24, 2014 - AstraZeneca Plc won backing from a European Union regulator for an ovarian-cancer drug, one of the experimental medicines the company cited as a reason for fending off Pfizer Inc.’s $117 billion takeover offer this year.
read article »

Europe Backs Continued Use of Ariad Pharma's Leukaemia Drug

(Reuters) Oct 24, 2014 - European regulators recommended continued use of Ariad Pharmaceuticals Inc's cancer drug, Iclusig, in its already approved indications to treat certain kinds of leukemia.
read article »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



70-Gene Signature Not Cost-Effective in Breast Cancer (Betty Hardwick Center/HealthDay News)

It would be interesting to see their analysis of OncoTypeDx in the same study setting. I know costs are very different...posted by: Winston Wong, PharmD

European Commission Approves IMBRUVICA(TM) in Two Forms of Blood Cancer (Johnson & Johnson)

The clinicals for Imbruvica are strong. The safety profile is clean. We actually have an a therapeutic advancement...posted by: Winston Wong, PharmD

Maine Hospitals See Price Increase For Specialty Cancer Drugs (Maine Public Broadcasting [Bangor, ME])

Not only a headache for Hospitals, but also a headache for payers. Limited distribution has been in place for...posted by: Winston Wong, PharmD

Bristol-Myers Squibb, Pharmacyclics and Janssen Announce Clinical Collaboration to Evaluate OPDIVO® (nivolumab) and IMBRUVICA®(ibrutinib) in Non-Hodgkin Lymphoma (Yahoo! Finance)

Two drugs which are very effective in their own right. Combined, project the results, and then the demand, and...posted by: Winston Wong, PharmD

ASCO Endorses CAP/IASLC/AMP Guideline on EGFR and ALK Molecular Testing for Patients with Lung Cancer (ASCO)

While I am glad to see ASCO endorsing such testing, such testing, from the eyes of the payer, is accepted as standard...posted by: Winston Wong, PharmD






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.




OBR Job Board


NCCN has posted 1 new job.


Bayer Biopharmaceuticals, Inc. has posted 20 jobs.


Ipsen Biopharmaceuticals, Inc. has posted over 50 jobs.


View OBR Job Board>>




The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
SNSS +19.58%
ZIOP +15.71%
FATE +9.22%
IMGN -5.10%
AVEO -4.90%
CVM -4.33%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: H2 2014
Company: Amgen
Product: Trebananib

Date: September / October 2014
Company: Seattle Genetics / Takeda
Product: Adcetris® (brentuximab vedotin)

Date: Q4 2014
Company: Bristol-Myers Squibb / Ono Pharmaceutical Co.
Product: Opdivo® (nivolumab)

See All OBR Radar items»